|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Stephen Allen Hurly M.B.A., M.Sc.||Pres, CEO & Director||N/A||N/A||1968|
|Mr. Peter Ros||VP of Fin.||N/A||N/A||1972|
|Mr. Edward F. Smith CPA||Chief Financial Officer||N/A||N/A||1971|
|Dr. Hans van der Vliet M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||1975|
|Ms. Amy Garabedian||Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Mr. Wouter van Hunnik||VP & Head of HR||N/A||N/A||N/A|
|Dr. Benjamin Winograd M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1957|
|Mr. Ton Adang Ph.D.||Chief Devel. Officer||N/A||N/A||1962|
|Dr. Paul W. H. I. Parren Ph.D.||Exec. VP, Head of R&D and Management Director||N/A||N/A||1964|
LAVA Therapeutics N.V., a clinical-stage biotechnology company, focuses on developing its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the potential treatment of solid tumors and hematological malignancies. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
El ISS Governance QualityScore de LAVA Therapeutics N.V., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.